Business
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing
About this update from Dogwood Therapeutics, Inc.
[{"type":"text","content":"ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced financial results for the fourth quarter and full year ended December 31, 2025. “The Company continues to execute at a high level, including recruitment of 143 patients in our ongoing Halneuron® Phase 2b trial, commencement of a Phase 2b extension trial and the recent execution of a financing to provide us with operational runway through the Phase 2b final data readout later this year,” said Greg Duncan, Chief Executive Officer of Dogwood Therapeutics. Key Highlights In December 2025, the Company announced the results of an interim analysis of the Halneuron® Phase 2b trial. The independent statistical review committee concluded that Halneuron® was separating from placebo in the 97 patient subset included in the analysis.The independent statistical review committee determined that a sample size of 210-240 is expected to provide 80-85% power to see a statistically significant Halneuron® pain reduction result versus placebo.CINP Phase 2b study is over 50% enrolled, Company expects top-line results in Q3 2026.In January 2026, the Company completed a financing of up to $26.9 million to progress Halneuron® through Phase 2b development, of which gross proceeds of $12.5 million have been received. Fourth Quarter 2025 Financial Results Research and development expenses for the fourth quarter of 2025 remained level with the fourth quarter of 2024 at $2.3 million. General and administrative expenses for the fourth quarter of 2025 were $1.5 million, compared to $5.2 million for the fourth quarter of 2024. The $3.7 million decrease quarter over quarter was primarily due to a decrease in nonrecurring transaction costs of $3.9 million related to the combination with Pharmagesic (Holdings) Inc. in October 2024 and a decrease in salaries and related personnel costs of $0.2 million offset by an increase in legal and professional fees of $0.3 million and expenses associated with being a public company of $0.1 million. Net loss attributable to common stockholders for the fourth quarter of 2025 was $3.8 million, or $0.26 basic and diluted net loss per share, compared to a net loss attributable to common stockholders of $8.2 million, or $...